Sunday, May 12 2024 | Time 18:22 Hrs(IST)
image
Business EconomyPosted at: May 5 2020 7:40PM


Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials

SAN DIEGO, May 5, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing services agreement with CytoDyn Inc., a late stage biotechnology company, for the supply of the investigational new drug, leronlimab (PRO 140), which is currently being used in clinical trial protocols for Mild-to-Moderately Ill and Severely Ill COVID-19 patients.
Aji Bio-Pharma provides high quality drug product aseptic fill finish services for CytoDyn. Leronlimab, a novel CCR5 antagonist with the potential for multiple therapeutic indications, has been and is currently being administered to COVID-19 patients at New York City area hospitals as part of an emergency investigational new drug (EIND), granted by the U.S. Federal Drug Administration (FDA) as part of Phase 1, Phase 2 and Phase 2b/3 clinical trials. CytoDyn is currently enrolling patients in two placebo-controlled randomized clinical trials for Phase 2 and Phase 2b/3.
"We are very excited to support CytoDyn's efforts to utilize this promising antibody therapeutic in the fight against COVID-19," said Kristin DeFife, Ph.D., Sr. VP of Operations & Site Head at Ajinomoto Bio-Pharma Services. "This partnership reinforces our company's mission to improve the health of humankind and underscores our vision statement being a leading, trusted, innovative partner to our clients and our people."
"We are extremely pleased to already have been collaborating with Aji Bio-Pharma for the production of leronlimab for other therapeutic indications, allowing us to quickly provide this therapeutic to COVID-19 patients in clinical trials," said Nader Pourhassan, Ph.D., President and CEO of CytoDyn. "Aji Bio-Pharma's drug product experience, infrastructure and strong regulatory track record were important to this partnership and in the timely supply of this therapeutic."
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client's needs. Learn more: www.AjiBio-Pharma.com
Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg
(Disclaimer--Features may vary depending on the regions; subject to change without notice.)
Please log in to get detailed story.
Tags: #Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials
More News

Kottayam-Kochi Rubber Market Rates

11 May 2024 | 9:04 PM

Kottayam, May 11 (UNI) Following were the Rubber Market rates announced by the Rubber Board here today per quintal
KOTTAYAM
RSS FOUR: 18050
RSS FIVE : 17800
KOCHI
RSS FOUR : 18050
RSS FIVE : 17800
UNI PA GNK.

see more..
Flipkart and Bajaj Auto team up to drive sustainable deliveries with Green Machines

Flipkart and Bajaj Auto team up to drive sustainable deliveries with Green Machines

11 May 2024 | 3:16 PM

Kolkata, May 11 (UNI) Bajaj Auto Ltd, the world's most valuable two-wheeler and three-wheeler company, and Flipkart, one of India's leading e-commerce marketplaces, on Saturday announced a strategic partnership to accelerate the adoption of electric vehicles (EVs) in the latter's last-mile delivery operations.

see more..

11 May 2024 | 2:52 PM

Mumbai, May 11 (UNI) Union Bank of India (UBI) reported a 19 percent year-on-year increase in the fourth quarter standalone net profit at ₹3,310.55 crore, supported by growth in net interest income (NII) and a sharp decline in loan loss provisions.

see more..

India's factory output grows 4 9 pc YoY in March 2024: Govt data

10 May 2024 | 8:24 PM

New Delhi, May 10 (UNI) India's factory output measured in terms of Index of Industrial Production (IIP) grew 4.9% year-on-year (YoY) in the month of March 2024, data from Ministry of Statistics & Programme Implementation (MoSPI) showed on Friday.

see more..

Kottayam-Kochi Rubber Market Rates

10 May 2024 | 7:43 PM

Kottayam, May 10 (UNI) Following were the Rubber Market rates announced by the Rubber Board here today per quintal
KOTTAYAM
RSS FOUR: 18050
RSS FIVE : 17800
ISNR TWENTY: 15300
SIXTY PERCENT LATEX: 13210
KOCHI
RSS FOUR : 18050
RSS FIVE : 17800
INTERNATIONAL RATES (BANGKOK)
RSS One : Not Available
RSS Two : Not Available
RSS Three: Not Available
RSS Four : Not Available
RSS Five : Not Available
KUALALUMPUR
SMR TWENTY :13752($164.70)
SIXTY PERCENT LATEX : 12999($155.70)
UNIPA GNK.

see more..
image